Join to View Full Profile
825 Eastlake Ave EMailstop LG-405Seattle, WA 98109
Phone+1 206-606-2022
Fax+1 206-606-1090
Dr. Safyan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 2018
University of WashingtonResidency, Internal Medicine, 2012 - 2014
Boston University Medical CenterResidency, Internal Medicine, 2011 - 2012
New York University School of MedicineClass of 2011
Certifications & Licensure
FL State Medical License 2021 - Present
WA State Medical License 2013 - 2026
NY State Medical License 2015 - 2024
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- RNA Precision Oncology in Advanced Pancreatic Cancer Start of enrollment: 2020 Dec 07
Publications & Presentations
PubMed
- Long-Term Survival Following Chemoradiation in Locoregional Recurrent GermlineMutated Pancreatic Ductal Adenocarcinoma.Rachael A Safyan, Keven Zhang, Smith Apisarnthanarax, Jonathan G Sham, Venu G Pillarisetty
Advances in Radiation Oncology. 2025-04-01 - S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE).Anwaar Saeed, Sarah Colby, Paul Eliezer Oberstein, Dan G Duda, Robin Park
Future Oncology. 2025-03-28 - HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma.Naomi Yamamoto, Stephanie Dobersch, Ian Loveless, Annie N Samraj, Gun Ho Jang
Clinical Cancer Research. 2025-02-17
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
